Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
US7153501B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 25, 2003 |
| Grant date | Dec 26, 2006 |
| Priority date | — |
| Expiry date | Jul 25, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/124
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Isolated, mammalian, bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin− HSC) contain endothelial progenitor cells (EPC) capable of forming retinal blood vessels. At least about 50% of the cells in the isolated Lin− HSC population include cell surface markers for CD31 and c-kit. Up to about 8% of the cells can include the Sca-1 cell marker, and up to about 4% of the cells can include the Flk-1/KDR marker. The isolated Lin− HSC populations of the present invention are useful for treatment of ocular vascular diseases. The isolated Lin− HSC populations that have been transfected with therapeutically useful genes are also provided, which are useful for delivering genes to the eye for cell-based gene therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.